ACTRN12606000286549CompletedPhase 1
A placebo-controlled, double-blind, randomised control trial using lycopene-rich supplements to reduce neutrophlic airway inflammation in asthma
Hunter New England Health Service0 sites139 target enrollmentStarted: July 7, 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Enrollment
- 139
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomised controlled trial
- Primary Purpose
- Treatment
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to ot stated (—)
- Sex
- All
Inclusion Criteria
- •Stable asthma, Non-smokers
Exclusion Criteria
- •Other respiratory disease, Vitamin or mineral use.
Investigators
Similar Trials
Recruiting
Phase 2
Investigator-initiated clinical trial on the effect of fluvoxamine to prevent exacerbation of COVID-19JPRN-jRCT2031220558iitsu Tomihisa80
Completed
Not Applicable
A randomised, double blind, placebo controlled comparative trial of Ceramide Cream and Ceramide Cleanser in the management of moderate eczema in adultsACTRN12615000782538Ego Pharmaceuticals Pty Ltd100
Recruiting
Phase 3
A double-blind, placebo-controlled, randomized withdrawal study of canakinumab in pyogenic sterile arthritis pyoderma gangrenosum and acne (PAPA) syndrome2024-517155-13-00IRCCS Istituto Giannina Gaslini24
Active, not recruiting
Not Applicable
A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance treatment of subjects with schizophreniaSchizophreniaEUCTR2011-001711-31-ITSUNOVION PHARMACEUTICALS INC.1,220
Active, not recruiting
Phase 1
A Phase 2 study to evaluate the Safety and Efficacy of CRN00808 for the treatment of acromegalyAcromegalyMedDRA version: 20.0Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disordersEUCTR2018-001833-42-HUCrinetics Pharmaceuticals, Inc.40